All In Biotech

Drug Trial Radar · NCT07155226

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Jan 9, 2026

Primary completion

Feb 15, 2029

Study completion Feb 15, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

Conditions

  • Acute Lymphoblastic Leukaemia
  • Acute Myeloid Leukaemia
  • Higher-risk Myelodysplastic Syndromes

Interventions

  • AZD3632Drug

    AZD3632 will be administered orally.

  • PosaconazoleDrug

    Posaconazole will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module 1: Number of participants with dose-limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)Time frame: Up to 3 years 1 month
  3. Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)Time frame: Up to 30 days after last dose (approximately 3 years 1 month)

Locations

30 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Decatur, Illinois · Recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Chapel Hill, North Carolina · Not yet recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Portland, Oregon · Suspended

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Fitzroy, Australia · Suspended

  • Research Site

    Perth, Australia · Suspended

  • Research Site

    Toronto, Ontario, Canada · Suspended

  • Research Site

    Montreal, Quebec, Canada · Suspended

  • Research Site

    Copenhagen, Denmark · Recruiting

  • Research Site

    Dresden, Germany · Recruiting

  • Research Site

    Frankfurt A. Main, Germany · Recruiting

  • Research Site

    Halle, Germany · Recruiting

  • Research Site

    Heidelberg, Germany · Recruiting

  • Research Site

    München, Germany · Recruiting

  • Research Site

    Ulm, Germany · Recruiting

  • Research Site

    Bologna, Italy · Recruiting

  • Research Site

    Ravenna, Italy · Recruiting

  • Research Site

    Bunkyō City, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Not yet recruiting

  • Research Site

    Okayama, Japan · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Edinburgh, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Manchester, United Kingdom · Recruiting

  • Research Site

    Newcastle, United Kingdom · Suspended

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.